Advertisement

Journal of Nuclear Cardiology

, Volume 26, Issue 1, pp 337–341 | Cite as

Isolated cardiac amyloidosis. Utility of bone seeking tracers scintigraphy in differentiating the subtype of amyloid: A case report

  • O. BourogianniEmail author
  • E. Papadaki
  • E. Foukarakis
  • S. Koukouraki
Images that Teach

Abstract

Background

Three types of amyloid are responsible for cardiac amyloidosis. Differentiation of the subtype is critical for the disease progression and the therapeutic decision.

Results

Myocardial scintigraphy using Tc-PYP is able to differentiate the cardiac amyloid subtype with high sensitivity and specificity. The myocardial uptake of PYP is higher in patients with TTR amyloidosis.

Conclusion

Non-invasive tests for the detection of cardiac amyloidosis, like myocardial scintigraphy with bone seeking tracers, can play a major role in the diagnosis progression and therapeutic management of patients with cardiac amyloidosis.

Keywords

Heart failure SPECT 99mTc 

Abbreviations

ATTR

Transthyretin-related amyloidosis

SSA

Senile systemic amyloidosis

AL

Light chain amyloidosis

CMRI

Cardiac magnetic resonance imaging

TTE

Transthoracic echocardiogram

RV

Right ventricular

LV

Left ventricular

H/CL

Heart to contralateral

PYP

Pyrophosphate

ATTRm

Hereditary transthyretin amyloidosis

Notes

Disclosure

O. Bourogianni, E. Papadaki, E. Foukarakis and S. Koukouraki as authors of this case report have nothing to declare.

References

  1. 1.
    Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S. The mosaic of the cardiac amyloidosis diagnosis: Role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014;15(12):1307-15.CrossRefGoogle Scholar
  2. 2.
    Galant NJ, Westermark P, Higaki JN, Chakrabartty A. Transthyretin amyloidosis: An under-recognized neuropathy and cardiomyopathy. Clin Sci. 2017;131(5):395-409.CrossRefGoogle Scholar
  3. 3.
    Perlini S, Mussinelli R, Salinaro F. New and evolving concepts regarding the prognosis and treatment of cardiac amyloidosis. Curr Heart Fail Rep. 2016;13(6):267-72.CrossRefGoogle Scholar
  4. 4.
    Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60.CrossRefGoogle Scholar
  5. 5.
    Sekijim Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225-33.CrossRefGoogle Scholar
  6. 6.
    Sekijima Y. Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036-43.CrossRefGoogle Scholar
  7. 7.
    Βois J, Chareonthaitawee P. Radionuclide imaging in congestive heart failure, assessment of viability, sarcoidosis, and amyloidosis. Cardiol Clin. 2015;34:119-32.Google Scholar
  8. 8.
    Bokhari S, Shahzad R, Castano A, Maurer M. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21(1):175-84.CrossRefGoogle Scholar
  9. 9.
    Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009;36(4):702-14.CrossRefGoogle Scholar
  10. 10.
    Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983;51(5):826-30.CrossRefGoogle Scholar
  11. 11.
    Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201.CrossRefGoogle Scholar
  12. 12.
    Falk RH. Senile systemic amyloidosis: Are regional differences real or do they reflect different diagnostic suspicion and use of techniques? Amyloid. 2012;19(Suppl 1):68-70.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2018

Authors and Affiliations

  • O. Bourogianni
    • 1
    Email author
  • E. Papadaki
    • 1
  • E. Foukarakis
    • 2
  • S. Koukouraki
    • 1
  1. 1.Department of Nuclear Medicine, Medical SchoolUniversity of CreteHeraklionGreece
  2. 2.Department of CardiologyVenizeleion General HospitalHeraklionGreece

Personalised recommendations